South Korea · Delayed Price · Currency is KRW IMBiologics Company Description
IMBiologics Corp., a biotechnology company, engages in developing immunomodulatory antibody therapeutics to treat autoimmune diseases and cancer.
The company uses Optimal Antibody Modality Manufacturing Technology (IM-OpDECon) for developing differentiated treatments for autoimmune diseases and immuno-oncology based on immuno-modulatory biologics.
Its products include IMB-101, a bispecific therapeutic antibody that targets OX40L and TNF to modulate pathological immune mechanisms mediating Th1/Th17 immune responses; IMB-102; IMB-201, an antibody-drug conjugate that targets HLA-G, a tumor-specific antigen; IMB-402, a concept anticancer vaccine bispecific antibody that utilizes the ePENDY (IgM-Agonist) modality to activate cancer cell-specific T cells.
IMBiologics Corp. was founded in 2020 and is based in Suwon-si, South Korea.
| Country | South Korea |
| Founded | 2020 |
| Industry | Biological Products, Except Diagnostic Substances |
| CEO | Gyongsik Ha |
Contact Details
Address: Gwanggyo Central Biz Tower Suwon-si, 16229 South Korea | |
| Phone | 82 31-8067-8172 |
| Website | imbiologics.com |
Stock Details
| Ticker Symbol | 493280 |
| Exchange | KOSDAQ |
| Stock Type | Common Stock |
| Reporting Currency | KRW |
| ISIN Number | KR7493280002 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Gyongsik Ha | Chief Executive Officer |
| Wanjun Kim | Chief Financial Officer |
| Insoo Jung | Chief Operating Officer |